Recent Advances in Nanocarrier-mediated Combination Drug Therapy for Tackling Solid-resistant Tumors
Km Rafiya1, Sakshi Awasthi2, Saba Asif Qureshi1
1Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Abstract:
Cancer is a group of dynamic diseases characterized by uncontrollable growth and spread of cells. The heterogenic nature of cancer hinders the abolishment of cancer resulting in a narrow therapeutic index, the capacity of drug efflux, multidrug resistance, and unacceptable side effects. The major challenge in the treatment of malignancies is multidrug resistance (MDR). A novel platform, nanoscale delivery system, concluding desirable applications for the treatment of cancer with targeted and controlled release of drugs, reducing the number of side effects and systemic toxicity. Recent studies emphasize that combining 2 or more nanocarrier-mediated therapies may produce complementary therapeutic effects, perhaps resulting in improved outcomes of cancer current therapies like deterioration of drug resistance. Therefore, in this article, we scrutinize the recent advancement addressing combination therapy by combining nanoparticles with anticancer drugs. It briefly concludes a thorough overview of cancer, tumor or solid resistant tumors, the mechanism of resistant tumors, current therapies for the treatment of solid tumors, and their challenges. It also covers various types of nanoparticles used in cancer treatment, the usage of nanocarriers in resistant tumors, and nanocarrier-based combinatorial therapy for the treatment of resistant tumors as well as its benefits. However, this approach still needs to be improved for clinical applications.
Insights
Nanoparticle-based combination therapy offers a promising strategy to overcome multidrug resistance (MDR) in cancer treatment by delivering drugs effectively and reducing side effects. Further research is needed for clinical application.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Cancer is a complex disease characterized by uncontrolled cell growth and spread.
- Multidrug resistance (MDR) presents a significant challenge in cancer therapy, leading to treatment failure and severe side effects.
- Conventional cancer treatments often have a narrow therapeutic index and systemic toxicity.
Purpose of the Study:
- To review recent advancements in nanoparticle-mediated combination therapy for cancer treatment.
- To explore the potential of nanocarriers in overcoming multidrug resistance in solid tumors.
- To highlight the benefits and challenges of nanocarrier-based combinatorial approaches.
Main Methods:
- Review of current literature on cancer, multidrug resistance mechanisms, and existing therapies.
- Analysis of various types of nanoparticles used in cancer treatment.
- Examination of nanocarrier applications in resistant tumors and combinatorial strategies.
Main Results:
- Nanoscale delivery systems offer targeted and controlled drug release, reducing side effects and systemic toxicity.
- Combining nanocarrier-mediated therapies can produce synergistic effects and potentially improve outcomes by combating drug resistance.
- Nanoparticle-based combination therapy shows promise for treating resistant tumors.
Conclusions:
- Nanocarrier-based combinatorial therapy is a promising approach to address challenges in treating solid tumors, particularly multidrug resistance.
- This strategy enhances therapeutic efficacy through targeted delivery and controlled release of anticancer drugs.
- Further optimization is required for successful clinical translation of nanocarrier-based combination therapies.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...